DrugId:  1
1. Name:  RAF-265
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in melanoma.
DrugId:  2
1. Name:  BCG vaccine
2. Groups:  Investigational
3. Description:  BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
4. Indication:  Not Available
DrugId:  3
1. Name:  Metrizamide
2. Groups:  Approved
3. Description:  Metrizamide is a solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.
4. Indication:  Metrizamide is used for lumbar, thoracic, cervical, and total columnar myelography to determine the presence of abnormalities in the spinal column, spinal canal, and central nervous system (CNS) as well as for cisternography by direct injection using standard radiologic techniques to visualize the basal cistern of the brain. For computerized tomography (CT) of the intracranial subarachnoid spaces and for ventriculography by direct injection using standard radiologic techniques to visualize the cerebral ventricles. Also used in pediatric angiocardiography to visualize lesions or malformations of the heart and obstructions or anomalies of the major thoracic vessels. Also used in adult peripheral arteriography to visualize specific regions of the vascular system and blood flow in such areas to help in the diagnosis and evaluation of neoplasms (known or suspected) or vascular diseases (congenital or acquired) that may cause changes in normal vascular anatomy or physiology. Metrizamide is also indicated in adults for intravenous digital arteriography of head and neck.
DrugId:  4
1. Name:  Enfortumab vedotin
2. Groups:  Investigational
3. Description:  Enfortumab vedotin has been used in trials studying the treatment of Tumors, Neoplasms, and Medical Oncology.
4. Indication:  Not Available
DrugId:  5
1. Name:  Panitumumab
2. Groups:  Approved, Investigational
3. Description:  Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
4. Indication:  For the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
DrugId:  6
1. Name:  Patritumab
2. Groups:  Investigational
3. Description:  Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
4. Indication:  Not Available
DrugId:  7
1. Name:  5-fluoro-2'-deoxycytidine
2. Groups:  Investigational
3. Description:  5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, and Urinary Bladder Neoplasms, among others.
4. Indication:  Not Available
DrugId:  8
1. Name:  Lumretuzumab
2. Groups:  Investigational
3. Description:  Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
4. Indication:  Not Available
DrugId:  9
1. Name:  Figitumumab
2. Groups:  Investigational
3. Description:  Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
4. Indication:  Not Available
DrugId:  10
1. Name:  Ganitumab
2. Groups:  Investigational
3. Description:  Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
4. Indication:  Not Available
DrugId:  11
1. Name:  Amatuximab
2. Groups:  Investigational
3. Description:  Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
4. Indication:  Not Available
DrugId:  12
1. Name:  Onartuzumab
2. Groups:  Investigational
3. Description:  Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
4. Indication:  Not Available
DrugId:  13
1. Name:  Duligotuzumab
2. Groups:  Investigational
3. Description:  Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.
4. Indication:  Not Available
DrugId:  14
1. Name:  Ascrinvacumab
2. Groups:  Investigational
3. Description:  Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
4. Indication:  Not Available
DrugId:  15
1. Name:  Atamestane
2. Groups:  Investigational
3. Description:  Atamestane has been used in trials studying the treatment of Breast Cancer, Breast Neoplasms, and Neoplasms, Hormone-Dependent.
4. Indication:  Not Available
DrugId:  16
1. Name:  APR-246
2. Groups:  Investigational
3. Description:  APR-246 has been used in trials studying the treatment of Prostatic Neoplasms, Hematologic Neoplasms, and Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53.
4. Indication:  Not Available
DrugId:  17
1. Name:  Sirna-027
2. Groups:  Investigational
3. Description:  Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular degeneration.
4. Indication:  Investigated for use/treatment in macular degeneration.
DrugId:  18
1. Name:  Tetrahydrouridine
2. Groups:  Investigational
3. Description:  Tetrahydrouridine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Sickle Cell Disease, and Head and Neck Cancer, among others.
4. Indication:  Not Available
DrugId:  19
1. Name:  ZD-6126
2. Groups:  Investigational
3. Description:  ZD6126 has been used in trials studying the treatment of Kidney Neoplasms, Colorectal Neoplasms, Metastases, Neoplasm, and Carcinoma, Renal Cell.
4. Indication:  Not Available
DrugId:  20
1. Name:  Mitometh
2. Groups:  Investigational
3. Description:  Mitometh is under investigation for the treatment of Adenocarcinoma, Oropharyngeal Neoplasms, Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer, and Stage IV Non-small Cell Lung Cancer, among others. Mitometh has been investigated for the treatment of Lung Neoplasms, Untreated Childhood Medulloblastoma, and Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor.
4. Indication:  Not Available
DrugId:  21
1. Name:  CP-547632
2. Groups:  Investigational
3. Description:  CP-547632 has been used in trials studying the treatment of Ovarian Cancer, Lung Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, and Fallopian Tube Cancer, among others.
4. Indication:  Not Available
DrugId:  22
1. Name:  Tremelimumab
2. Groups:  Investigational
3. Description:  Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies.
4. Indication:  Not Available
DrugId:  23
1. Name:  Sizofiran
2. Groups:  Investigational
3. Description:  A beta-D-glucan obtained from the Aphyllophoral fungus Schizophyllum commune. It is used as an immunoadjuvant in the treatment of neoplasms, especially tumors found in the stomach. Sizofiran has been used in trials studying the treatment of Cervical Cancer.
4. Indication:  Not Available
DrugId:  24
1. Name:  Lapachone
2. Groups:  Investigational
3. Description:  Lapachone has been used in trials studying the treatment of Cancer, Carcinoma, Advanced Solid Tumors, Head and Neck Neoplasms, and Carcinoma, Squamous Cell.
4. Indication:  Not Available
DrugId:  25
1. Name:  MK-1496
2. Groups:  Investigational
3. Description:  MK-1496 has been used in trials studying the treatment of Neoplasms and Malignant.
4. Indication:  Not Available
